Cancers & treatments·Regimen libraryCurative

Pola-R-CHP

Checked 2026-09-09

Untreated DLBCL, IPI 2-5

One cycle

every 21 days × 6 · about 18 weeks in total

21-day cycle × 6, then rituximab alone cycles 7-8 (about 18 weeks)IntravenousOral Daily oral course

Components

Drug	Dose	Route	Days
Polatuzumab vedotin ADC	1.8 mg/kg	IV	D1
Rituximab Monoclonal antibody (anti-CD20, chimeric)	375 mg/m²	IV	D1
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug)	750 mg/m²	IV	D1
Doxorubicin Cytotoxic chemotherapy (anthracycline)	50 mg/m²	IV	D1
Prednisone	100 mg once daily	Oral	D1-5

Cycles

6, then rituximab alone cycles 7-8

21-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Recommended

Notes

Vincristine is replaced by polatuzumab; G-CSF primary prophylaxis was mandated in POLARIX.

Used in

Diffuse large B-cell lymphoma

Trials

POLARIX

Products

Polatuzumab vedotinRituximabCyclophosphamideDoxorubicin

Source

POLARIX, NEJM 2022

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.